Clinical trials: Alteplase
Ischemic Stroke
Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke
Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) has been the only proven therapy for acute ischemic stroke (AIS) for almost 20 years.
- Trial name
- SWIFT DIRECT (NCT03192332)
- Testing
- Stent-retriever thrombectomy with revascularization device of the Solitaire™ type, Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)
- Where
- 48 sites in Austria, Canada and 6 more
- Volunteers
- 410 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Ischemic Stroke
Microbubbles and Ultrasound in Stroke Trial: MUST Study
To determine whether transcranial 2-MHz ultrasound combined with intravenous administration of microbubbles improves early recanalization in patients with acute ischemic stroke caused by middle cerebral artery (MCA) proximal…
- Trial name
- NCT00222040
- Testing
- Ultrasound, Levovist
- Where
- 5 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Tissue Plasminogen Activator, Intraventricular Brain Hemorrhage
CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance
The study aims to investigate the effect of continuous tPA irrigation into the ventricles. Investigators believe it may be superior to the traditional every 8-hour bolus dosing and continuous isotonic solution irrigation alone.
- Trial name
- NCT07643493
- Testing
- Tissue Plasminogen Activator (tPA), Isotonic solution
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- David Dornbos
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30…
- Trial name
- ORIGINAL (NCT04915729)
- Testing
- tenecteplase, alteplase
- Where
- 55 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Thrombosis
Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants
The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age.
- Trial name
- NCT00265005
- Testing
- alteplase
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Louisville
Menstrual Bleeding, Heavy
PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis
The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding.
- Trial name
- NCT05862805
- Testing
- Sample Collection and Endometrial Biopsy
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke, Alteplase Adverse Reaction
the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients
The investigators evaluated the impact of AF on different subtypes of post-alteplase hemorrhagic transformation of brain infarction.
- Trial name
- NCT06653946
- Testing
- Alteplase
- Where
- Egypt
- Volunteers
- 716 people
- Sponsor
- Kafrelsheikh University
Plastic Bronchitis, Protein-Losing Enteropathies
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic bronchitis (PB) is a rare, most often pediatric disease characterized by the formation of obstructive airway casts primarily composed of fibrin.
- Conditions
- Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
- Trial name
- PLATyPuS (NCT02315898)
- Testing
- Treatment-inhaled tPA
- Where
- 6 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Catheter Obstruction, Vascular Access Devices
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion
This is a multicentre, open-label, randomised, phase III study designed to evaluate the efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD
- Trial name
- NCT01958164
- Testing
- Actilyse, Saline solution
- Where
- 5 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
Coronary artery disease is the leading cause of death in USA. Contemporary cardiac care has substantially reduced mortality and morbidity in patients with severe coronary artery disease.
- Trial name
- NCT00868855
- Testing
- Bradykinin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vanderbilt University
Ischemic Stroke
Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke
BACKGROUND: Alteplase dissolves blood vessel clots in acute ischemic stroke and is the only approved acute drug treatment <4½ hours of stroke onset.
- Trial name
- NOR-TEST (NCT01949948)
- Testing
- Tenecteplase, Alteplase
- Where
- 13 sites in Norway
- Volunteers
- 1,050 people
- Sponsor
- Lars Thomassen
Stroke, Acute, Thromboses, Intracranial
Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke
The proposed trial is a pragmatic, registry linked, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25…
- Trial name
- AcT (NCT03889249)
- Testing
- Tenecteplase, Alteplase
- Where
- 22 sites in Canada
- Volunteers
- 1,600 people
- Sponsor
- University of Calgary
Ischemic Stroke
Predictors of Outcome in t-PA Treated Stroke.
Stroke is among the most disabilitating diseases worldwide in terms of numbers affected and its consequences. A relatively new and well documented treatment of acute ischemic stroke today is tPA (tissue plasminogen activator…
- Trial name
- NCT01498042
- Where
- Norway
- Volunteers
- 162 people
- Sponsor
- Sorlandet Hospital HF
Central Retinal Artery Occlusion
A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.
- Trial name
- THEIA (NCT03197194)
- Testing
- Alteplase, acetylsalicylic acid
- Where
- 17 sites in France
- Volunteers
- 70 people
- Sponsor
- Nantes University Hospital
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Submacular Hemorrhage, Ruptured Retinal Arterial Macro Aneurysms
Submacular Hemorrhage Associated With Retinal Arterial Macro Aneurysm
Evaluation of surgical outcome of vitrectomy with subretinal injection of recombinant tissue-plasminogen activator for submacular hemorrhage associated with retinal arterial macroanuerysms.
- Trial name
- NCT02120066
- Testing
- Vitrectomy for submacular hemorrhage, subretinal injection of tissue-plasminogen activator
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Kyorin University
Subretinal Haematoma Linked to AMD
Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications
AMD is a disease of the central retina, a zone that enables fine detail activities (reading, detail…). This central zone of the retina can be affected by a haemorrhagic complication when small abnormal vessels suddenly start to…
- Trial name
- STAR (NCT02557451)
- Testing
- Surgery, Intravitreal injections of gas, injections of an antiangiogenic
- Where
- 17 sites in France
- Volunteers
- 91 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder
Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]
The purpose of this protocol is to conduct a pilot prospective non-blind clinical trial to evaluate the efficacy and safety of a novel saline irrigation technique as an adjunct to standard interventions for treating retained…
- Conditions
- Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
- Trial name
- [LYTICS+] (NCT06713382)
- Testing
- Pleural Saline Irrigation
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Beth Israel Deaconess Medical Center